Skip to content
Surviving

Turtle / Donchian Breakout

Donchian-channel breakout trend-following

Passes 9 of 11 gates. Profit factor 1.61, Sharpe 0.90, placebo PASS, deflated-Sharpe 0.997. It fails only on max drawdown (−49%) and instrument concentration (43%). A genuine trend edge — it survives, pending a risk re-scope before any capital.

Category
Trend
Window
2014–2026 (12.5y)
Instruments
Diversified futures-style basket
Timeframe
Daily (Donchian breakout)
Tested
2026-06-24
1.61Profit factor
0.90Sharpe
-49.0%Max drawdown
38.8%Win rate
590Trades
9/11Gates passed
PASSPlacebo

A real edge that fails on risk, not signal

The Turtle / Donchian-channel breakout — buy the N-day high, ride the trend, exit on the opposite channel — is the strongest survivor in the program to date. Over 12.5 years (2014–2026) it passes 9 of 11 pre-registered gates: profit factor 1.61, Sharpe 0.90, positive in 92% of calendar years, a deflated Sharpe of 0.997, and a placebo PASS (real PF 1.61 vs the random-breakout 95th percentile of 1.48 — only 0.8% of permutations beat it). The 2× cost stress still clears at PF 1.55.

It fails exactly the two gates that trend-following famously strains: max drawdown −49% (gate: ≤12%) and instrument concentration 43% (gate: ≤40%). Both are risk-shape failures, not edge failures — which is why the status is SURVIVING, not RETIRED.

Gate scorecard — 9 / 11

#GateResultPass
1≥ 100 trades590
2PF ≥ 1.20 net1.61
3Sharpe ≥ 0.60.90
4Max DD ≤ 12%−49.0%
5Positive in ≥ 60% of years92%
6Bootstrap 95% LB Sharpe > 00.58
7Placebo: real PF > p951.61 vs 1.48
82× cost stress PF > 1.01.55
9Deflated Sharpe positiveDSR 0.997
10No instrument > 40% of P/L43%
11Walk-forward OOS ≥ 0.9× ISholds

What survival means here

This is the honest middle ground the framework exists to surface. The edge is statistically real and survives the kill-shot placebo and the deflated-Sharpe correction for multiple testing — the things that retire most strategies. What it does not yet have is a risk profile a small account can hold: a −49% drawdown will end most live deployments long before the trend pays off, and 43% of the P/L riding on one instrument is fragile.

The disciplined next step is a re-pre-registration with lower per-instrument risk and a broader basket, evaluated on a fresh window — not a post-hoc tweak to make this run pass. Survival earns a Round 2, not capital.

Verdict: SURVIVING (9/11). Real edge, wrong risk shape. The trend signal is genuine and placebo-confirmed; the −49% drawdown and 43% concentration must be re-scoped before this could clear all eleven gates and earn a paper allocation.

Charts & evidence

Turtle Donchian breakout equity curve
Equity curve, 2014–2026 — final equity ~$1.17M on the modelled base, PF 1.61.
Turtle placebo distribution
Placebo PASS: real PF 1.61 beats the random-breakout 95th percentile of 1.48; only 0.8% of permutations match it.
Turtle drawdown
Max drawdown −49% — the gate it fails, and the well-documented cost of riding trends.
Per-instrument P/L
Profit concentration: the top instrument carries 43%, just over the 40% gate.
Turtle walk-forward
Walk-forward out-of-sample performance holds relative to in-sample.

Frequently asked

Does the Turtle trading system still work in 2026?

The signal still carries a real edge. Run over 2014–2026 through a pre-registered 11-gate battery, the Turtle / Donchian-channel breakout system posts a profit factor of 1.61, a Sharpe of 0.90, and a deflated Sharpe of 0.997, and it beats a random-breakout placebo. It passes 9 of 11 gates — the two failures are a −49% max drawdown (the classic trend-following deep-drawdown profile) and 43% profit concentration in one instrument. It is a survivor under evaluation, not yet a deployment-cleared strategy.

Why is the Turtle system not marked Validated despite passing 9 of 11 gates?

Because two of the gates it fails are real risk constraints, not technicalities. A −49% max drawdown exceeds the 12% gate by a wide margin, and 43% of profit comes from a single instrument (the 40% concentration limit). The trend edge is statistically genuine — placebo-confirmed, deflated-Sharpe positive — but the risk profile needs to be re-scoped (lower per-instrument risk, broader basket) before it could clear all eleven and earn capital.

Methodology: The Validation Gauntlet — pre-registered spec, 11-gate battery, real market data. Full reproducible report: backtests/turtle/results.json in the source repository. Author: Brent Akamine (Founder, Vinovest). Backtests are not investment advice.